IBCSG 25-02 / BIG 3-02 (TEXT)

  • A phase III trial evaluating the role of exemestane plus GnRH analogue as adjuvant therapy for premenopausal women with endocrine responsive breast cancer

    Tamoxifen and Exemestane Trial (TEXT)

  • Study Chairs
    BIG: Dr. Olivia Pagani - Mendrisio, Switzerland
    US Intergroup: Dr. Barbara Walley - Calgary, Canada

    Statistician
    Dr. Meredith Regan

    Trial Coordinator
    Meredith Kissel, Dorene Polizzi

    Data Managers
    Monica Greco, Adriana Mora de Karausch


    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Date of Activation
    August 4, 2003

    Date of Closure
    March 11, 2011

    Targeted Accrual
    2639 patients

    Final Accrual
    2672 patients

     

    Global completion dates
    October 23, 2024

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login